Healthcare stocks were trading with losses, with the S&P BSE Healthcare index decreasing 95.91 points or 0.44% at 21486.84 at 13:47 IST. Among the components of the S&P BSE Healthcare index, Neuland Laboratories Ltd (down 2.61%), Unichem Laboratories Ltd (down 2.43%),Marksans Pharma Ltd (down 2.33%),Alembic Pharmaceuticals Ltd (down 2.15%),Fortis Healthcare Ltd (down 1.98%), were the top losers. Among the other losers were Take Solutions Ltd (down 1.94%), Shilpa Medicare Ltd (down 1.9%), Granules India Ltd (down 1.84%), IOL Chemicals & Pharmaceuticals Ltd (down 1.71%), and Strides Pharma Science Ltd (down 1.7%). On the other hand, Lincoln Pharmaceuticals Ltd (up 4.61%), Bliss GVS Pharma Ltd (up 3.52%), and Astrazeneca Pharma India Ltd (up 2.27%) turned up.
Healthcare stocks slide business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Healthcare stocks were trading in the positive zone, with the S&P BSE Healthcare index rising 119.43 points or 0.56% at 21594.79 at 09:48 IST. Among the components of the S&P BSE Healthcare index, Marksans Pharma Ltd (up 5.42%), Suven Pharmaceuticals Ltd (up 4.41%),Novartis India Ltd (up 3.99%),Morepen Laboratories Ltd (up 3.83%),Neuland Laboratories Ltd (up 2.79%), were the top gainers. Among the other gainers were Alembic Ltd (up 2.79%), RPG Life Sciences Ltd (up 2.43%), Glenmark Pharmaceuticals Ltd (up 2.29%), Strides Pharma Science Ltd (up 2.04%), and Indoco Remedies Ltd (up 2.04%). On the other hand, Suven Life Sciences Ltd (down 4.96%), Dishman Carbogen Amcis Ltd (down 2.6%), and IOL Chemicals & Pharmaceuticals Ltd (down 2.15%) moved lower.
Strides receives USFDA approval for Oxybutynin Chloride Tablets
Posted On: 2020-12-18 02:41:57 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.
According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride Tablets USP, 5 mg is approximately US$ 29 Mn. The product will be manufactured at the company s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
Technavio Research: Global Primary Sclerosing Cholangitis Treatment Market 2020-2024 | Post-Pandemic Analysis and Forecast for New Normal | Technavio
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005678/en/
Technavio has announced its latest market research report titled Global Primary Sclerosing Cholangitis Therapeutics Market 2020-2024 (Graphic: Business Wire)
For a More Detailed Analysis,
Get a Free Sample Report Delivered Instantly
The report on the primary sclerosing cholangitis treatment market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by rise in the number of liver transplants and UDCA treatments.